AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02527356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ride-On Cars with Standing Postures (ROC-Sit)
Description: Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
Study NCT02527356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Therapy Program
Description: The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. In addition, they will receive training program in a hospital for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention. The participants will also experience the two 30-minute car driving sessions during the whole 2-hour training. The difference between the regular therapy group and the two ROC groups is the experience of car driving is controlled by the therapist, i.e. passive locomotion. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
Study NCT00700804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
Study NCT00700804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Protein Diet
Description: High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
Study NCT00299988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Study NCT00299988 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02116621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trialist Intervention
Description: Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
Study NCT02116621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone
Study NCT02972320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: temozolomide maintain therapeutic
Study NCT01983644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECO flow restoration device
Description: RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
Study NCT01983644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR flow restoration device
Description: Solitaire FR flow restoration device has been approved by the FDA and CFDA.
Study NCT02452502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
Study NCT02452502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
Study NCT01992822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental pain induction
Description: application of a pre-fixed pressure (160 kPa) on the forearm.
Study NCT01275222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
Study NCT01275222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 600mg/day (Glevec is the brand name for imatinib)
Description: Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
Study NCT01275222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 800mg/day (Glevec is the brand name for imatinib)
Description: Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
Study NCT04590456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEMF
Description: group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
Study NCT03540186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigenorm Antivir
Description: 1 capsule of Epigenorm Antivir twice daily for 3 months
Study NCT03540186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
Study NCT04942392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital dance for PD
Description: The digital dance class was held via Zoom. The class was scheduled once a week for 60 min and consisted of 10 sessions. A professional, certified Dance for PD and experienced dance instructor was teaching the dance class. The dance classes followed the Dance for PD protocol yet was adjusted to fit the digital zoom format.
Study NCT03653520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: 5 or 10mg
Study NCT03653520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50mg or 100mg
Study NCT03653520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 1 or two tabs
Study NCT03653520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKO melt
Description: 1 or 2 MKO melts
Study NCT02277444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab 80 mg/m\^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
Study NCT02277444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA >=1.67 m\^2) weekly at least through Week 28.
Study NCT01591356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EphA2-targeting DOPC-encapsulated siRNA
Description: Given IV
Study NCT01591356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01591356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03637660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine Penicillin
Description: BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
Study NCT03637660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine Penicillin
Description: BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
Study NCT04645680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume isocaloric whole foods diet higher in fiber
Study NCT04645680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Whole foods diet
Study NCT04645680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04645680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04645680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04645680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03629678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile health application
Description: The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
Study NCT02761057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of plasma and serum samples
Study NCT02761057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT01444300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: 10mg, bid, pill taken by mouth for 12 weeks
Study NCT02761057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT02761057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01444300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill, bid for 12 weeks
Study NCT02761057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 0.5 mg
Description: Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 1.5 mg
Description: Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
Study NCT02761057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Given PO
Study NCT02761057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT03849820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted partial nephrectomy
Description: Application of the da Vinci surgical robot to assist the partial nephrectomy
Study NCT03849820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open partial nephrectomy
Description: Open surgery to conduct the partial nephrectomy
Study NCT04721912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic dietary supplement
Description: GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 4 mg
Description: Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
Study NCT04533529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant tablet will be administered orally once daily.
Study NCT04533529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet will be administered orally once daily.
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 12 mg
Description: Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
Study NCT04030455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04030455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04030455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT04030455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Undergo IO intervention
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Undergo IO intervention
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Undergo IO intervention
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo counseling
Study NCT02079662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo IO intervention
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02079662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04801264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga-PSMA will be used to image lesions of adenoid cystic carcinoma by PET/CT.
Study NCT03961672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO
Study NCT03538041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally.
Study NCT04801264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Description: Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Study NCT00643084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low residue diet/no standard bowel preparation
Description: low residue diet/no standard bowel preparation
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 36 mg
Description: Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 100 mg
Description: Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942: Fed State
Description: Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942: MAD Part
Description: Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
Study NCT03151486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.
Study NCT00490542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone (Geodon)
Description: ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
Study NCT04641897 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Respiratory rate modification
Description: During the Low RR and High RR periods, respiratory rate will be set depending on baseline ABG and according a nomogram so as to have an approximate difference of 10 points between groups, while maintining PaCO2 and pH values within safety limits (pH 7.20 to 7.45, and PaCO2 35 to 60 mmHg).~Once defined the target respiratory rate, this will be decreased or increased in 4 points each 30 to 45 min, and ABG repeated at 2 hours. At this time, changes will be made to keep PaCO2 and pH values within safety limits, and ABG repeated at 6 and finally 12 hours.~During the whole period, inspiratory to expiratory ratio will be maintained constant, and only changed to keep inspiratory time above 0.6 seconds (usually at high resp rate).
Study NCT02027909 — intervention group
Intervention type: DEVICE
Intervention: Reprogramming dual chamber pacemaker
Description: Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
Study NCT00643084 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard bowel preparation
Description: standard bowel preparation
Study NCT01741844 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
Study NCT01162226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gait and balance training program
Description: The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
Study NCT00414765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Study NCT02171637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: escalating doses
Study NCT03533270 — intervention group
Intervention type: PROCEDURE
Intervention: Urethroplasty
Description: Surgical repair of Urethral injury
Study NCT03555305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study NCT03555305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Administered SC
Study NCT03642769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid administration
Description: Fluid administration of bolus and maintenance fluids
Study NCT03642769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: Fluid administration of bolus and maintenance fluids
Study NCT03928886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode
Description: Patient-assisted mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.